Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dih
ydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as
analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as pote
ntial candidates for gene-directed enzyme prodrug therapy, All the phthalim
ides are poor substrates for Escherichia coli nitroreductase compared to CB
1954, However, 6, 7, 10 and 11 are reduced by both the human and rat forms
of DT-diaphorase; 10 is a particularly good substrate but 7 decomposes in
phosphate buffer. A cell-line panel consisting of V79 cells that have been
engineered to express various levels of either the human or rat forms of DT
-diaphorase in an identical cellular background was used to evaluate these
compounds as prodrugs activated by this enzyme. The cytotoxic effect of CB
1954 is proportional to the activity of either the rat or human enzyme but
cells expressing the rat enzyme were much more sensitive (10 000-fold at hi
gher levels of DT-diaphorase activity) than cells expressing comparable lev
els of the human enzyme. These results demonstrate that the resistance of h
uman tumors to CB 1954 can be accounted for solely by the kinetic propertie
s of the enzyme for this prodrug, The nitrophthalimide analogs overcome thi
s kinetic failing of CB 1954. However, these compounds are not activated to
produce cytotoxicity in these DT-diaphorase-expressing cell lines. It is p
ostulated their reduction products fail to undergo an acylation reaction in
a manner analogous to CB 1954, Thus, reduction by DT diaphorase is not pre
dictive of cytotoxicity in this class of prodrugs, [(C) 1999 Lippincott Wil
liams & Wilkins].